Description
ADCC-Enhanced anti-Ebola Sudan Boniface Virus Glycoprotein (17F6) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Ebola Sudan Boniface virus infections
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Ebola Sudan Boniface Virus Glycoprotein antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Ebola GP
Full Name
Ebola Sudan Boniface Virus Glycoprotein
Background
Ebola Sudan Boniface virus GP Monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutic treatment of Ebola Sudan Boniface virus infections in vitro and in vivo.
Alternative Names
Ebola Sudan Boniface Virus Glycoprotein; Ebola Glycoprotein; Ebola GP
Cellular Localization
Virion membrane, Host cell membrane
Involvement in Disease
Diseases associated with GP1BA include Pseudo-Von Willebrand Disease and Bernard-Soulier Syndrome, Type A2, Autosomal Dominant.
Related Pathways
Its related pathways are Formation of Fibrin Clot (Clotting Cascade) and amb4 Integrin signaling.
Function
GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium.
Post-translational modifications
1.Glycocalicin is the product of a proteolytic cleavage/shedding, catalyzed by ADAM17, which releases most of the extracellular domain. Binding sites for vWF and thrombin are in this part of the protein 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn37, Asn175, Thr308, and Asn362 4.Glycosylation from GlyConnect
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
17F6
Description
The antibody to Ebola GP can be used for the detection, prevention, and/or therapeutical treatment of Ebola virus infections in vitro and in vivo.
Antibody Indication
Ebola Sudan Boniface virus infections
Ebola Sudan Boniface virus infections
